COVIRNA
A PROGNOSTIC TEST FOR COVID-19 PATIENTS

A diagnostic test to improve surveillance and care of COVID-19 patients

COVIRNA is a patient-centred Innovation Action aiming to generate a diagnostic tool to identify COVID-19 patients at risk of developing fatal cardiovascular complications, ultimately leading to their improved surveillance and care.

In particular, the project will complete and deploy a prognostic system based on cardiovascular biomarkers of COVID-19 clinical outcomes, combined with a predictive model built on digital tools and artificial intelligence analytics.

ABOUT COVIRNA

The goal of COVIRNA is to conduct a large retrospective study on multiple existing cohorts of COVID-19 patients throughout Europe and upscale the already validated and patented "FIMICS" panel of cardiac-enriched long noncoding RNA biomarkers into an in-vitro diagnostic test (COVIRNA), adapted to COVID-19 patients.

Building on the network developed within the EU-CardioRNA COST Action, 15 partners pooled their expertise and resources to build a multidisciplinary and multicentre study with the common aim to improve individualised surveillance, care and follow-up of COVID-19 patients in the context of the current pandemic.

COVIRNA will pursue throughout the 24 months of activities **the goal of**:

- Generating a diagnostic test based on cardiovascular RNA biomarkers highly predictive of the clinical outcomes of COVID-19 patients

- Enabling the rapid market uptake of the diagnostic test with the aim to improve individualised surveillance, care and follow-up of patients in the context of the current pandemic.

Tech & research level: build a biobank; achieve biomarker qualification & select a subset of highly specific lncRNAs predictive of COVID-19; design an in vitro diagnostic test to predict COVID-19 clinical outcomes.

Socio-economic & regulatory level: Achieve CE marking of the new COVIRNA prognostic; establish a strategic consultation; raise stakeholders' awareness on the solution and sharing practical knowledge on it.

COVIRNA
Methodologies to achieve the goals

OUR CONSORTIUM

The COVIRNA Consortium brings together 15 **partners, from 11 EU Member States and 1 non-EU Member State**.

Partners can be clustered around three main types:

- 12 Research institutions;
- 2 Business sector institutions;
- 1 Non-governmental organisation

Research

- Luxembourg Institute of Health (LU)
- University of Luxembourg (LU)
- Imperial College of Science and Technology Medicine (UK)
- University of Maastricht (NL)
- University of Leipzig (DE)
- Jožef Stefan Institute (SI)
- Fundació Privada Institut de Recerca de l`Hospital de la Santa Creu i Sant Pau (SP)
- University of Coimbra (PT)
- Heinrich-Heine-University of Düsseldorf (DE)
- The University of Edinburgh (UK)
- International University of Sarajevo (BA)
- San Donato Polyclinic SPA (IT)

Business

- Firalis SA (FR)
- Pharmahungary 2000 Kft (HU)

Non-governmental

- European Health Management Association (EHMA);

COVIRNA

GET INVOLVED

Governmental and funding bodies are cordially invited to become involved in COVIRNA, among others through the opportunity to join its Stakeholder Platform.
This can help in staying informed and providing inputs for the diagnostic tool development more actively

covirnacomms@outlook.com   www.covirna.eu   @Covirna_EU